SERUM HYPERVISCOSITY SYNDROME
SERUM HYPERVISCOSITY SYNDROME
复制标题
DOI：
10.1001/jama.1965.03080190030008
复制
发表时间：
1965-01-01
影响因子：
--
通讯作者：
SOLOMON, A
中科院分区：
文献类型：
--
作者：
FAHEY, JL;BARTH, WF;SOLOMON, A
临床症状反映出血清中的高粘滞性。高粘滞综合征通常与巨球蛋白血症有关，偶尔还与多发性骨髓瘤有关。这些不同的高粘度表现的共同特征是对降低血清异常蛋白水平的反应，从而降低血清粘度。血浆法已成功地用于降低血清巨球蛋白和高切黏度，消除高黏滞症候群，促进主客观改善。每个患者似乎都有一个症状阈值，即与临床症状发作相关的相对粘度水平。症状阈值由巨球蛋白的性质和浓度以及决定个体对粘度升高的易感性的宿主因素确定。
Clinical symptoms are noted which reflect hyperviscosity in the serum. The hyperviscosity syndrome is usually associated with macroglobulinemia, and, occasionally, with multiple myeloma. The common feature in these varied manifestations of hyperviscosity is the response to lowering the serum level of anomalous protein and, thus, the serum viscosity. Plasmagphersis has been used successfully to reduce serum macroglobulins and excessive viscosity, to eliminate hyperviscosity symptomatology and induce subjective and objective improvement. Each patient appears to have a symptomatic threshold, ie, a relative viscosity level which is associated with the onset of clinical symptomatology. The symptomatic threshold is determined by the properties and concentration of the macroglobulin and by host factors which determine the vulnerability of individuals to elevated viscosity.